Using a national health insurance database, the authors compared elderly psoriasis patients (≥65 years) treated with biologic agents, including IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), the IL-12/23p40 inhibitor (ustekinumab), and TNF-α inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol), against matched controls receiving non-biologic systemic therapies such as methotrexate, acitretin, apremilast, or ciclosporin. Here, IL17A is linked to psoriasis.